Abstract
To estimate healthcare resource utilization (HCRU) and cost of cytokine release syndrome (CRS) and/or neurotoxicity (NT) management by grade among patients with relapsed/refractory multiple myeloma (RRMM) who received ide-cel, a BCMA-directed CAR T-cell therapy, in the KarMMa clinical trial (NCT03361748).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have